Additional work is likely to yield APOBEC3B inhibitors, and such molecules may have therapeutic merit in high-risk individuals and/or as a post-operative adjuvant to limit further tumor evolution and improve the durability and efficacy of existing therapeutics. This evidence concerns the gene APOBEC3B and neoplasm.